Icon (NASDAQ:ICLR) Director Ciaran Murray Sells 10,000 Shares of Stock

Icon Plc (NASDAQ:ICLR – Get Free Report) Director Ciaran Murray sold 10,000 shares of the company’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $200.18, for a total transaction of $2,001,800.00. Following the completion of the transaction, the director owned 7,000 shares in the company, valued at approximately $1,401,260. This trade represents a 58.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Ciaran Murray also recently made the following trade(s):

  • On Monday, November 2nd, Ciaran Murray sold 3,452 shares of Icon stock. The stock was sold at an average price of $205.66, for a total transaction of $709,938.32.

Icon Price Performance

Icon stock opened at $191.40 on Tuesday. The stock has a market capitalization of $14.66 billion, a P/E ratio of 32.94, a P/E/G ratio of 11.11 and a beta of 1.19. Icon Plc has a 12-month low of $66.57 and a 12-month high of $219.04. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.32 and a quick ratio of 1.32. The firm’s 50-day moving average is $179.55 and its two-hundred day moving average is $147.45.

Icon (NASDAQ:ICLR – Get Free Report) last posted its quarterly earnings data on Tuesday, October 27th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.62 by $0.04. The business had revenue of $2.02 billion during the quarter, compared to analyst estimates of $2.01 billion. Icon had a net margin of 5.45% and a return on equity of 7.73%. The company’s revenue was down .9% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.31 earnings per share. Equities analysts predict that Icon Plc will post 9.71 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on ICLR shares. Weiss Ratings raised shares of Icon from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, October 28th. UBS Group increased their price target on Icon from $195.00 to $236.00 and gave the stock a “neutral” rating in a research note on Thursday, October 29th. William Blair upgraded Icon to a “strong-buy” rating in a report on Thursday, July 30th. Barclays raised their price objective on Icon from $175.00 to $230.00 and gave the stock an “equal weight” rating in a report on Thursday, October 29th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $235.00 price objective on shares of Icon in a research report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Icon has an average rating of “Moderate Buy” and an average price target of $213.76.

View Our Latest Stock Analysis on ICLR

Institutional Investors Weigh In On Icon

Several hedge funds have recently modified their holdings of ICLR. Pathstone Holdings LLC raised its stake in Icon by 15.5% during the third quarter. Pathstone Holdings LLC now owns 29,193 shares of the medical research company’s stock worth $4,962,000 after purchasing an additional 3,927 shares during the period. First Trust Advisors LP boosted its holdings in shares of Icon by 330.5% in the 3rd quarter. First Trust Advisors LP now owns 8,654 shares of the medical research company’s stock valued at $1,471,000 after purchasing an additional 6,644 shares during the last quarter. Heartland Advisors Inc. grew its stake in shares of Icon by 17.7% during the 3rd quarter. Heartland Advisors Inc. now owns 53,974 shares of the medical research company’s stock valued at $9,175,000 after buying an additional 8,131 shares during the period. Stephens Investment Management Group LLC grew its stake in shares of Icon by 7.1% during the 3rd quarter. Stephens Investment Management Group LLC now owns 771,246 shares of the medical research company’s stock valued at $131,104,000 after buying an additional 50,985 shares during the period. Finally, Muhlenkamp & Co. Inc. increased its holdings in shares of Icon by 1.1% during the 3rd quarter. Muhlenkamp & Co. Inc. now owns 67,038 shares of the medical research company’s stock worth $11,396,000 after buying an additional 701 shares during the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Icon Company Profile

(Get Free Report)

ICON plc is a global contract research organization (CRO) that provides outsourced development services to pharmaceutical, biotechnology, medical device and government organizations. Its work supports the development of medicines and other healthcare products from early research through clinical trials and regulatory submission. The company’s services include clinical trial design and management, data management and biostatistics, regulatory support, laboratory services, medical imaging and patient recruitment.

Read More

Insider Buying and Selling by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.